This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wester, H.-J. Search for Related Content PubMed PubMed Citation Articles by Wester, H.-J. Related Collections Therapeutics and Targets Therapeutics and Targets: Identification, Validation, and Markers Tumor Biology Tumor Biology: Model Organisms and Imaging

Nuclear Imaging Probes: from Bench to Bedside

Author's Affiliation: Department of Nuclear Medicine, Technische Universität München, Munich, Germany

Requests for reprints: Hans-Jürgen Wester, Department of Nuclear Medicine, Technische Universität München, Ismaninger Strasse 22, 81675 Munich, Germany. Phone: 49-89-41-40-45-86/49-89-41-40-29-73; E-mail: h.j.wester{at}lrz.tum.de.

Abstract

The availability of specific imaging probes is the nuclear fuel for molecular imaging by positron emission tomography and single-photon emission computed tomography. These two radiotracer-based imaging modalities represent the prototype methods for noninvasive depiction and quantification of biochemical processes, allowing a functional characterization of tumor biology. A variety of powerful radiolabeled probes—tracers—are already established in the routine clinical management of human disease and others are currently subject to clinical assessment. Emerging from investigations of the genomic and proteomic signatures of cancer cells, an increasing number of promising targets are being identified, including receptors, enzymes, transporters, and antigens. Corresponding probes for these newly identified targets need to be developed and transferred into the clinical setting. Starting with a brief summary of the characteristics and prerequisites for a "good tracer," an overview of tracer concepts, target selection, and development strategies is given. The influence of the imaging concepts on tracer development is also discussed.

This article has been cited by other articles:

				A. J. Sinusas, F. Bengel, M. Nahrendorf, F. H. Epstein, J. C. Wu, F. S. Villanueva, Z. A. Fayad, and R. J. Gropler Multimodality Cardiovascular Molecular Imaging, Part I Circ Cardiovasc Imaging, November 1, 2008; 1(3): 244 - 256. [Full Text] [PDF]

				H. C. Manning, A. Lander, E. McKinley, and N. J. Mutic Accelerating the Development of Novel Molecular Imaging Probes: A Role for High-Throughput Screening J. Nucl. Med., September 1, 2008; 49(9): 1401 - 1404. [Abstract] [Full Text] [PDF]

				G. C. Prendergast Non-Invasive Imaging: Enhancing Preclinical Research and Evidence-Based Medicine Cancer Reviews Online Content, July 1, 2007; 2007(4): 7 - 7. [Full Text] [PDF]

				R. G. Blasberg Imaging Update: New Windows, New Views Clin. Cancer Res., June 15, 2007; 13(12): 3444 - 3448. [Full Text] [PDF]